磷的摄取每天应限制在1200 毫克以下,并须配合 磷结合剂(Phosphate Binders)的服用。尿毒症病人也可能出现高血镁症 (Hypermagnesemia),使骨质病变更加惡化,故应避免使用氢氧化镁或 氧化镁等含镁之抗酸剂。
基于6个网页-相关网页
Historically, treatment with oral phosphate binders was intended to prevent symptomatic secondary hyperparathyroidism.
依据既往经验,口服磷酸盐结合剂有助于治疗系统性继发性甲旁亢。
Treatment typically consists of dietary phosphate restriction and phosphate binders—medications that work like a sponge to soak up phosphate in the gut.
这种治疗通常包括限制磷酸盐饮食和使用磷酸盐结合剂,后者像海绵一样吸收肠内磷酸盐。
In this article we review the rationale for treatment with oral phosphate binders, discuss evidence that supports the use of available agents, and suggest an approach for clinical practice.
在这篇文章中,我们归纳了口服磷酸盐结合剂的治疗机制,讨论使用该药的支持证据,并提出临床使用的建议。
应用推荐